Enterprise Value
7.069B
Cash
647.9M
Avg Qtr Burn
-103.8M
Short % of Float
7.73%
Insider Ownership
0.92%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AYVAKIT (avapritinib) Details PDGFRA mutant GIST (Gastrointestinal Stromal Tumors) | Approved Quarterly sales | |
GAVRETO (parlsetinib) Details Non-small cell lung carcinoma, Thyroid cancer, Cancer, Solid tumor/s | Approved Quarterly sales | |
AYVAKIT® (avapritinib) Details Systemic Mastocytosis | Approved Quarterly sales | |
BLU-945 +/- osimertinib Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Update | |
BLU-222 (CDK12) Details Breast cancer, Cancer | Phase 1/2 Update | |
BLU-451 Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Update | |
Elenestinib Details Systemic Mastocytosis | Phase 1 Data readout |